jRCT2031240009已完成不适用
SJP-0154 Phase 2 - Multicenter, Randomized, double-Masked, Placebo controlled Parallel-Group Study in Patinets with Dry Eye Disease -
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 330
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Aged over 18 years at the time of the informed consent (any gender)
- •Live in Japan
- •Have continuous subjective symptoms of dry eye disease
- •Tear film break-up time of <= 5 seconds
- •Meet the other protocol-specified inclusion criteria may apply
排除标准
- •Unable to discontinue wearing contact lens during the study
- •Have a history of, or scheduled corneal transplantation during the study
- •Have a history of, or scheduled permanent punctal occlusion during the study
- •Have used or anticipates use of a punctal plug during the study -Have a history of, or scheduled ocular surface surgery during the study
- •Have ophthalmic disease other than dry eye disease -Have disease that affects subjective symptoms of dry eye -Have known history of hypersensitivity or serious adverse reaction to any of the study drug ingredients -Unable to discontinue any ophthalmic medicines including OTC, except test drug for ophthalmic examination during the study -Female participant who is pregnant, potentially pregnant, lactating or intents to become pregnant. And unable to obtain a consent to practice adequate contraception during the study -Male participant who does not agree to practice adequate contraception and not to donate sperm during the study
- •Have judged that it is inappropriate to participate in this study by investigator
- •Meet the other protocol-specified exclusion criteria
结局指标
主要结局
-
Change from baseline in dry eye symptoms
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
Placebo Controlled, Parallel-Group Study of SJP-0049 in Patients with Allergic ConjunctivitisAllergic ConjunctivitisjRCT2031250103Senju Pharmaceutical Co., Ltd.112
已完成
不适用
Randomized, placebo-controlled Phase I study of SJP-0008 in healthy adult volunteers (single and repeated dose study)Healthy adultsJPRN-UMIN000019104Senju Pharmaceutical co.,ltd.90
已完成
不适用
A double-blind placebo-controlled pilot study of safety and tolerability of AIMSPRO® in established diffuse cutaneous systemic sclerosisDiffuse cutaneous systemic sclerosisMusculoskeletal DiseasesSystemic sclerosisISRCTN54813778Daval International Ltd (UK)20
已完成
不适用
A phase I clinical pharmacology study of SJP-0139 with a single-dose and multiple-dose administration in healthy male volunteersJapanese healthy adult male volunteersJPRN-UMIN000030621Senju Pharmaceutical Co.,Ltd.12
已完成
不适用
A phase I clinical pharmacology study of SJP-0125Primary open-angle glaucoma (broad definition) or ocular hypertensionJPRN-UMIN000031296Senju Pharmaceutical Co.,Ltd.18